Unique ID issued by UMIN | UMIN000051323 |
---|---|
Receipt number | R000058544 |
Scientific Title | Comprehensive Analysis of Imaging and Intraocular Bioactive Factors in Macular Edema |
Date of disclosure of the study information | 2023/06/12 |
Last modified on | 2023/06/12 11:26:18 |
Comprehensive Analysis of Imaging and Intraocular Bioactive Factors in Macular Edema
Analysis of Imaging and Intraocular Bioactive Factors in ME
Comprehensive Analysis of Imaging and Intraocular Bioactive Factors in Macular Edema
Analysis of Imaging and Intraocular Bioactive Factors in ME
Japan |
Macular edema
Ophthalmology |
Others
NO
To examine the relationship between treatment efficacy and ocular cytokine kinetics in macular edema.
Others
Anti-VEGF treatment efficacy (visual acuity, central retinal/choroidal thickness, flare, blood flow, sensitivity, vascular density) in relation to cytokine concentration
Visual acuity, central foveal retinal thickness/choroidal thickness, flare, blood flow, sensitivity, vascular density
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Injection of anti-VEGF agents 0.05 ml (first time and at the inactivate interval)
20 | years-old | <= |
90 | years-old | > |
Male and Female
1. Patients with macular edema
2. Patients with visual acuity of 40/50 or less and central foveal retinal thickness of 300 micro m or more
3. Patients over 20 years old
4. Patients scheduled to receive anti-VEGF agents and expected to continue for at least 12 months
5. Patients who have not been treated with laser, surgery, or injection at other hospitals
6. Patients who have been informed of the purpose and content of this study and have given their free and voluntary consent.
7. Patients who are able to visit the hospital and undergo examinations during the observation period.
1. Patients undergoing other ocular surgery or intravitreal injection of various drugs
2. Patients with the following diseases (Patients with active uveitis, patients with iris neovascularization, patients with poorly controlled glaucoma
3. Other patients who are judged to be inappropriate as subjects by the principal investigator or a research associate.
4. Patients who refuse to cooperate in this study.
100
1st name | Hidetaka |
Middle name | |
Last name | Noma |
Tokyo Medical University Hachioji Medical Center
Department of Ophthalmology
193-0998
1163 Tatemachi, Hachioji, Tokyo
0426655611
nomahide1122@gmail.com
1st name | Hidetaka |
Middle name | |
Last name | Noma |
Tokyo Medical University Hachioji Medical Center
Department of Ophthalmology
193-0998
1163 Tate-machi, Hachioji, Tokyo
0426655611
nomahide1122@gmail.com
Tokyo Medical University
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Tokyo Medical University Medical Ethics Committee
6-7-1 Nishi-Shinjuku, Shinjuku, Tokyo
0333426111
adm_irb@tokyo-med.ac.jp
NO
2023 | Year | 06 | Month | 12 | Day |
Unpublished
Open public recruiting
2023 | Year | 06 | Month | 03 | Day |
2023 | Year | 06 | Month | 03 | Day |
2023 | Year | 06 | Month | 12 | Day |
2026 | Year | 03 | Month | 31 | Day |
2023 | Year | 06 | Month | 12 | Day |
2023 | Year | 06 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058544
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |